FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second Line Treatment of Colorectal Cancer

FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second Line Treatment of Colorectal Cancer Martin H. Cohen, Joe Gootenberg, Patricia Keegan, Richard Pazdur Oncologist 2007; 12: 356-361 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine and FDA information, and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Add bevacizumab (Avastin®) to the FOLFOX4 chemotherapy regimen. Evaluate the contribution of bevacizumab and FOLFOX4 to treatment results. Understand FDA criteria for the analysis of response rate and progression-free survival. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 3, 2007 Most Recent Review: Apr. 3, 2007* Most Recent Update: Apr. 3, 2007 Date Credit Expires: Apr. 3, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course